Introduction {#Sec1}
============

Causality assessment is one of the central functions in pharmacovigilance. While there is no single widely accepted approach to determine causality, the Bradford Hill criteria are generally regarded as a comprehensive method available for this purpose. The criteria are multidimensional in the sense that nine distinct aspects of causal inference for an observed association between a specific agent and a disease (or drug and adverse event) are assessed; namely these are strength of association, consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment, and analogy. Originally described in January 1965 by Sir Austin Bradford Hill, a pioneering English epidemiologist, the eponymous criteria have been used in epidemiology for more than 50 years, and regarded as a model for assessing causality in pharmacovigilance \[[@CR1]--[@CR4]\].

Integration of Human Smell and Taste Functions {#Sec2}
----------------------------------------------

Although served by distinct receptors and first-order neurons, smell and taste are intimately entwined at the cortical perceptual interfaces, which results in comprehensive and intense olfactory-gustatory integration \[[@CR5], [@CR6]\]. For example, the so-called gestalt experience of food flavor is much more than the mere sum of smell and taste elements; the percept of umami---the fifth taste---is another example. Such near complete integration and indeed super-additive perception of the two senses has been attributed to the extensive anatomical connections of several brain areas with both the primary gustatory and olfactory cortex and enhanced coupling of the limbic and temporal lobes. Excellent reviews of this fascinating topic are available \[[@CR7], [@CR8]\].

Humans perceive odors via two distinct pathways: via nostrils (e.g., sniffing) and via mouth (drinking and eating) called orthonasal and retronasal olfaction, respectively. The former occurs during inspiration and the latter occurs during expiration \[[@CR9], [@CR10]\]. Retronasal olfaction is essential for flavor perception and is frequently confused with taste. Apparently, the confusion is so deep rooted that some languages do not have distinct words for "smelling" and "tasting" \[[@CR10]\]. Taste is served by four cranial nerves (trigeminal, facial, glossopharyngeal, and vagus), which may explain why isolated impairment of taste is uncommon and true loss of taste is very rare \[[@CR11], [@CR12]\].

It is well known that only about 5% of all patients visiting smell and taste clinics actually suffer from taste disorders while about 95% of the patients have smell disorders \[[@CR11], [@CR13]\]. Therefore, in clinical practice the recommended first step is to rule out smell impairment in all cases of self-reported taste impairments \[[@CR14]\]. Of the five special senses only smell and taste have *not* evolved as full-fledged medical/clinical specializations; dedicated smell and taste clinics are quite rare even in the developed world \[[@CR15]\].

As a result of these factors and because smell and taste alterations in most individual case safety reports (ICSRs) are self-reported, it is very difficult to separate the two and ascertain true taste problems; therefore, the two adverse events were regarded as a single entity for the purpose of this causality assessment.

Mechanisms of Drug-Induced Smell and Taste Loss {#Sec3}
-----------------------------------------------

Hundreds of prescription-only and over the counter (OTC) medicines are associated with smell and taste dysfunction \[[@CR16]\]. For the majority of drugs, specific mechanisms leading to the occurrence of smell and taste alterations remain unknown \[[@CR17]\]. Proposed theoretical mechanisms include primary effects of the offending drugs and secondary or collateral effects. Agonistic or antagonistic actions of drugs, modulation of neuronal action potential, alteration of neurotransmitter function, and changes in interplay between neural networks in CNS-associated perception of sense of smell and taste are proposed primary mechanisms. Some drugs have secondary effects like drying up of mucus secretion, reducing access to chemosensory receptors, altered chemistry or ionic milieu of receptors (change in constituents of mucus or saliva). Bitter taste of the offending drugs is often the only mechanism widely known to be responsible.

Intranasal Fluticasone Propionate {#Sec4}
---------------------------------

Intranasal fluticasone propionate (INFP), first approved in 1990, is an established therapeutic option for treatment of allergic rhinitis. It is also approved for the treatment of nasal polyposis in some countries outside the USA. Like other intranasal corticosteroids, such as beclomethasone dipropionate, budesonide, flunisolide, mometasone furoate monohydrate, and triamcinolone acetonide, INFP is labeled for the adverse events of *alterations or loss of sense of smell and taste*; this is primarily based on spontaneous case reports received during post-approval clinical use.

On the basis of evidence from anecdotal reports and controlled clinical trials, the empirical use of corticosteroids (intranasal, oral, and injectable) has evolved to fill the current therapeutic void to some degree. This paradoxical body of evidence presents unique challenges to the causality assessment of olfactory and gustatory dysfunction associated with INFP. It is remarkable that currently there are *no medicines*---*approved or in development*---for the treatment of smell and taste disorders, notwithstanding their increasing prevalence, negative consequences on quality of life, and significant unmet medical need. Specifically, none of the corticosteroids are indicated for use in the treatment of smell and taste disorders.

To the best of the authors' knowledge, this is the first comprehensive causality assessment of the relationship between intranasal corticosteroids and smell and taste dysfunction. In this narrative review, the Bradford Hill criteria are applied to assess whether exposure to INFP is causally linked to olfactory and gustatory dysfunction. This review also aims to demonstrate challenges inherent to causal inference that have been eloquently alluded to by Sir Bradford Hill as "...in what circumstances can we pass from this observed *association* to a verdict of *causation*?" \[[@CR1]\].

A review of case reports of "taste and smell alterations" reported to the GlaxoSmithKline global safety database from March 1990 to August 2017 was independently performed by the authors. The Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (PT) included were ageusia, anosmia, dysgeusia, hypergeusia, hypogeusia, hyposmia, and parosmia. Evidence relevant to the Hill criteria in the context of drug-induced olfactory and gustatory dysfunction was obtained from peer-reviewed published literature (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Schematic representation of Hill's criteria for causality assessment and corresponding bodies of evidence or data. *INFP* intranasal fluticasone propionate, *ICSR* individual case safety reports, *AR* allergic rhinitis, *NP* nasal polyposis, *PEA* phenyl ethyl alcohol

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Application of the Bradford Hill Criteria {#Sec5}
=========================================

Strength of Association {#Sec6}
-----------------------

A measure of strength of association is the comparative frequency of occurrence of smell and taste dysfunction in the general population versus the patient population exposed to INFP.

From March 1990 (first approval of INFP) to August 2017, GlaxoSmithKline's Global Clinical Safety and Pharmacovigilance Department received 914 cumulative case reports of smell and taste problems associated with INFP (includes ageusia, anosmia, dysgeusia, hypergeusia, hypogeusia, hyposmia, and parosmia), during which the estimated cumulative exposure was 32.2 million patient years (prescriptions) and 46 million OTC units (based on Intercontinental Medical Statistics (IMS) data). During the same period, the FDA Adverse Event Reporting System (FAERS) database included 385 cases of taste and smell alterations. The number of duplicate cases in the two databases is not known.

Well-known limitations of case reports include poor quality of narratives, absent or incomplete information, absence of key details regarding dechallenge and rechallenge, and concurrent medications. Assuming the worst-case scenario of causality in *all* reported cases (regardless of poor quality/un-assessable narratives, presence of confounding factors---background disease, concurrent medications known to cause smell and taste alterations, and absence of details of dechallenge and rechallenge) and assuming the worst-case scenario that only 1 in 100 events is reported because of underreporting of adverse events \[[@CR18], [@CR19]\], the total extrapolated number of reported cases would be 129,900 (i.e., \[914 + 385\] × 100). On this basis, the frequency of occurrence of smell and taste alterations is estimated to be approximately 1.66 in 1000 subjects (0.166%), \[(129,900) ÷ (46 + 32.2 million)\]. In comparison, the frequency of smell and taste alterations in the general population is 6--12% for self-reported olfactory impairments \[[@CR20]--[@CR22]\] and 5.7--13.3% for self-reported gustatory impairments \[[@CR23], [@CR24]\].

Furthermore, it is well known that olfactory dysfunction is a hallmark symptom of allergic rhinitis with frequency ranging from 10% to 88% (mode range, 20--40%) \[[@CR25]--[@CR27]\].

In the general population dysgeusia (altered sense of taste) is reported in up to 34% of patients with smell and taste disorders \[[@CR11]\] but true ageusia is very rare \[[@CR28]\]. In one study of 240 patients with allergic rhinitis, objective assessments (olfactometry by Elsberg and Levy's method and electrogustometry) revealed that the incidence of smell and taste disorders in patients with allergic rhinitis is 21.4% and 31.2%, respectively \[[@CR29]\]. Unfortunately, there is a paucity of epidemiological studies of taste disorders in allergic rhinitis and nasal polyposis.

Evidence described above shows that the frequency of occurrence of olfactory and gustatory dysfunction on exposure to INFP is orders of magnitude lower than the corresponding frequencies in the general population and patients with allergic rhinitis; hence the likelihood of causality is not supported. As Hill noted, absence of strength of association per se does not rule out causality.

Consistency {#Sec7}
-----------

In Hill's original context of epidemiology, "consistency" addressed whether the association between agent and disease was observed regardless of place, time, and circumstance. In pharmacovigilance, it has been defined as reproducibility of the drug--event pair at two levels: positive dechallenge and positive rechallenge at the level of individual case safety report (ICSR) and at an aggregate level where patterns of related factors contributing to reproducibility are assessed. A higher consistency strengthens the likelihood of causal inference \[[@CR30]\].

On the basis of a recent review of global safety databases, very few cases (approximately 1.0%) reported positive dechallenge and positive rechallenge. Owing to the very low number of cases with adequate details of rechallenge and dechallenge, no consistent pattern of factors contributing to reproducibility was observed. The review also found a significant number of cases that describe persistence of smell and/or taste problems regardless of discontinuation of INFP therapy.

As a result of confounding by pre-existing sinonasal diseases that contribute to high background prevalence of the adverse events of interest, it is difficult to delineate consistent patterns of association between INFP therapy and smell and taste problems. Fortuitously fluticasone propionate (FP) formulations are available for administration via inhaled and topical dermal routes. These non-intranasal formulations of FP provide an opportunity to circumvent this issue. Use of inhaled FP (metered dose inhalers, dry powder inhalers, and nebules) was very rarely associated with smell and taste problems and these cases were confounded by concurrent sinonasal diseases and concurrent medications. There were no reports of smell and taste problems associated with cutaneous formulations (cream and ointment) of FP. A search of the literature found no reports of smell and taste alterations linked to these formulations.

In clinical trials of FP dry powder *administeredvia* *swallowing* in the treatment of eosinophilic esophagitis, smell or taste dysfunctions were not reported \[[@CR31]--[@CR33]\]. Following maxillary sinus irrigation with FP mixed in large volumes of saline for treatment of acute and chronic rhinosinusitis, smell and taste problems have not been reported \[[@CR34], [@CR35]\]. As non-intranasal formulations of FP are devoid of smell and taste problems there is lack of consistency of association.

Specificity {#Sec8}
-----------

This is a measure of reproducibility of the event in specific situations; the likelihood of causality would be stronger when the association is observed in a specific population or a specific geographic location and the disease or event has no other valid explanation.

In the context of pharmacovigilance, specificity is interpreted as the occurrence of a drug--event pair under precise and narrowly defined circumstances and patient subsets; rarity of occurrence of the event in the general population and patients unexposed to the drug would add heft to the likelihood of causation. In other words, specificity asks the question: to what degree is the event solely attributable to the given drug?

Smell and taste alterations have numerous diverse etiologies ranging from common cold to cancer chemotherapy; in addition, factors such as advancing age, gender, smoking, alcohol consumption, poor dental oral hygiene, educational and social standards are known to alter or reduce perception of smell and taste \[[@CR36]\]. Chronic conditions such as renal or hepatic failure, HIV infection, cancer, complicated type 2 diabetes mellitus, Parkinson's disease, Alzheimer's disease, Bell's palsy, cognitive impairment, and multiple sclerosis are principal causes of olfactory and gustatory dysfunction \[[@CR14]\].

One of the most common causes of anosmia is sinonasal diseases, an umbrella term for seasonal and perennial allergic rhinitis, chronic rhinosinusitis with or without nasal polyps, and upper respiratory tract infections \[[@CR37], [@CR38]\].

It is estimated that more than 200 commonly prescribed medicines are linked to olfactory and gustatory dysfunction \[[@CR39], [@CR40]\]. In the context of sinonasal diseases many of the medications used concurrently are known to be linked to smell and taste alterations. For instance, intranasal zinc, an OTC medicine available for therapy of common cold, is frequently associated with smell and taste loss that is occasionally reported to be persistent. Macrolide antibiotics, used to treat upper respiratory tract infections that commonly occur in subjects with allergic rhinitis, are most frequently associated with olfactory and gustatory dysfunction \[[@CR17]\].

Therefore, smell and taste dysfunction are essentially due to diverse etiology. In most cases, valid alternative explanations would be available and weaken the likelihood of causal inference. Finally, an analysis of the case reports provides no evidence of specific and reproducible patterns of relationship between smell and taste alterations and exposure to INFP.

Temporality {#Sec9}
-----------

In the context of causal inference, temporality has the distinction of being the only *sine qua non* criterion. Hill observed that causality cannot be assumed if the adverse event *occurs prior to* drug exposure.

A recent systematic review of olfaction in allergic rhinitis found that frequency of olfactory dysfunction ranged widely from 10% to 88% of patients, with most studies reporting frequencies in the range of 20--40% \[[@CR27]\]. Characteristically, olfactory dysfunction fluctuates over time on the basis of severity of allergic rhinitis and related sinonasal diseases. Patients tend to exhibit a continuum of olfactory loss ranging from mild to progressively severe across the spectrum of allergic rhinitis, nasal polyposis, chronic rhinosinusitis, and upper respiratory tract infections \[[@CR41]\]. Upper respiratory tract infections due to viral etiology frequently complicate allergic rhinitis via inflammatory damage to olfactory epithelium, which in turn aggravates fluctuations of olfactory performance and loss \[[@CR38]\]. Fluctuations may also be physiological because of the cyclical apoptosis and regeneration of receptors throughout life; human olfactory receptor cells and gustatory receptor cells have a life-span of about 30--60 days and 10 days, respectively \[[@CR12]\]. Hence in most subjects with allergic rhinitis and nasal polyposis the likelihood of presence of smell and taste dysfunction *prior to exposure* to INFP cannot be ruled out.

Time to onset of smell and taste alterations associated with use of INFP in most case reports was poorly documented. In 313 cases the time to onset was reported and ranged from immediate to 20 years; no consistent pattern of onset was observed.

Biological Gradient (Dose--Response Curve) {#Sec10}
------------------------------------------

When the degree of response (event) is commensurate with the magnitude of exposure to an agent (offending drug), a positive dose response is said to support an observed association, and such evidence is of considerable importance as it would strengthen causal inference. The majority of case narratives did not provide details of dose, frequency, or both. In the few reports that provided details of dosing, INFP dose varied from one spray per nostril once daily to two sprays per nostril twice daily. Case safety reports did not provide adequate data to support or refute a relationship between dose of INFP and degree of smell and taste alterations. Also, a search of the literature did not find studies addressing this question.

Paradoxically there is some evidence of dose response from anecdotal reports and clinical trials that show clinically significant beneficial effects of INFP on olfactory and gustatory performance. These data tend to support a positive dose--response curve (see Table [1](#Tab1){ref-type="table"}). In terms of olfactory improvement, fluticasone propionate nasal drops (FPND) 400 mcg bid was the most effective, followed by FPND 400 mcg od and fluticasone propionate aqueous nasal spray (FPANS) 200 mcg bid while FPANS 200 mcg od was moderately effective \[[@CR42]--[@CR44]\] (see "[Experiment](#Sec13){ref-type="sec"}" for details). However, the dose--response curve and optimal dose of INFP or other corticosteroids in improving smell and taste performance have not been established.Table 1Improvements in olfactory and gustatory performance reported in clinical trials of patients with allergic rhinitis or nasal polyposis treated with intranasal fluticasone propionateStudyKey detailsEndpointOutcomeCommentsKlimek et al. \[[@CR68]\]Prospective observational study\
Allergic rhinitis patients mild (*n* = 6), moderate (*n* = 27), and severe (*n* = 14). Intranasal azelastine 548 mcg + INFP200 mcg combination spray\
Treatment duration 3 monthsAnosmia in allergic rhinitis\
Recovery measured by TDI (threshold, determination, and identification) scoreSignificant improvement in olfactory function with restoration of normosmia in 44/47 (94%) at 1 month and in all 47 patients at 3 monthsFirst study to show normosmia was achieved in all patients; azelastine reportedly has bitter taste. Unfortunately, effect on taste function was not assessedYe \[[@CR67]\]Non-randomized clinical trial. Patients (*n* = 55) with chronic rhinosinusitis with nasal polyps\
FPANS 400 mcg bid for 3 months after FESS\
Follow-up 1 yearSubjective improvement in olfactionSignificant improvement in olfaction in most patientsSignificant correlation between olfactory scores and eosinophil counts at 1 yearVaidyanathan et al. \[[@CR43]\]Controlled clinical trial nasal polyposis (*n* = 60)\
Period 1: oral prednisolone 25 mg/days or placebo for 2 weeks\
Period 2 both groups: FPND 400 mcg bid, for 8 weeks and then FPANS 200 mcg bid for 18 weeksPolyp size, nasal symptoms, hyposmia scoreInitial prednisolone therapy followed by topical FP is more effective than topical\
FP alone in reducing polyp size and improving olfactionFPND and FPANS sustained improvement of hyposmia over 28 weeksOlsson et al. \[[@CR66]\]Nasal polyps with asthma post FESS\
FPND 400 mcg bid or placebo\
Treatment duration 14 weeks (*n* = 68)QoL SF-36\
Sense of smell assessedFPND arm significant improvement in sense of smell and 3 other SF-36 domainsStudy showed FPND improves sense of smell as well as QoLJankowski et al. \[[@CR42]\]Nasal polyposis\
3 periods: acute, maintenance, and follow-up; duration in months 1, 1, and 6, respectively\
Group 1 FPANS 400 mcg bid in all 3 periods (*n* = 79). Group 2 FPANS spray 400 mcg bid in period 1; 200 mcg od during periods 2 and 3 (*n* = 82). Group 3 placebo during periods 1 and 2, FPANS 200 mcg bid in period 3 (*n* = 81). Treatment duration 8 monthsPeak nasal inspiratory flow rate (PNIF); symptom scoresPNIF and symptom scores improved; 200 mcg bid was more effective at all end points. Sense of smell and sense of taste improved significantlyThe only study to report improved smell and taste (significant at 1 month *p* \< 0.001 and *p* \< 0.05 for smell and taste, respectively)Vlckova et al. \[[@CR65]\]Nasal polyposis FPANS 400 mcg bid or placebo\
Treatment duration 12 weeks (*n* = 109 recruited, 106 completed)Nasal symptoms including anosmiaSignificantly reduced polyp size; significant sustained reduction in nasal symptoms and anosmia at weeks 4, 8, and 12FPANS was administered via breath actuated deviceDemirel et al. \[[@CR64]\]Nasal polyposis\
FPANS 100 mcg bid\
FPND 400 mcg od\
FPND 400 mcg bid\
Treatment duration 12 weeks (*n* = 34)Polyp size reduction\
Nasal symptoms including anosmiaSignificant reduction polyp size at 4, 8, and 12 weeks with twice daily dose\
Significant recovery of olfaction only with\
FPND 400 mcg bid doseShows dose response of INFPRowe-Jones et al. \[[@CR63]\]Nasal polyposis post FESS\
FPANS 200 mcg bid (*n* = 55)\
Placebo (*n* = 54)\
Treatment duration 5 years (*n* = 109, 77 with nasal polyps, 72 completed 5 years)Nasal symptoms improvementOlfaction significantly improved in FPANS arm at 1 and 2 years post operationLongest duration study to date. FPANS group required significantly less rescue medication and had significantly less polyp recurrence over 5 yearsAukema et al. \[[@CR62]\]Nasal polyps awaiting surgery\
FPND (*n* = 27)\
Placebo (*n* = 27)\
Treatment duration 12 weeksNeed for surgery\
Nasal symptoms including anosmiaFPND eliminated need for surgery in 13 of 27 vs. 6 of 27 in placebo group\
FPND group achieved significant reduction in loss of smell (*p* = 0.004)All patients had received intranasal corticosteroid spray for 3 months (with no satisfactory result) before entry. Majority of patients in both groups had previous sinus surgeries for polypsDijkstra et al. \[[@CR60]\]Nasal polyps awaiting FESS\
INFP 400 mcg bid\
INFP 800 mcg bid\
Placebo\
Treatment duration 1 year (*n* = 162 recruited, 59 completed)Nasal symptoms including anosmiaNo difference in any outcome between the three groupsPatients were non-responders to corticosteroidsBlomqvist et al. \[[@CR61]\]Anosmia\
Pre-trial open phase (*n* = 40 anosmia patients): 10-day therapy with oral prednisolone 40 mg od for 3 days, tapering by 5 mg/day. Concurrent FPANS 200 mcg per day. Those with ≥ 2 step improvement in butanol odor test entered blinded phase\
Blinded phase:\
FPANS (*n* = 20), placebo (*n* = 10), controls (*n* = 10). Treatment duration 6 monthsEffect of FPANS on olfaction during long-term therapySignificant improvement in sense of smell after the 10-day open phase; during blinded phase the olfactory improvement remained at the same level in placebo and FPANS groups but deteriorated sharply in the control group23/40 patients had upper respiratory tract infection; treatment with local corticosteroids does not restore olfactory function in those with damage to olfactory epitheliumPenttilä et al. \[[@CR44]\]2 weeks run in\
FPND 400 mcg od (*n* = 48), FPND 400 mcg bid (*n* = 47), placebo (*n* = 47). Treatment duration 12 weeks, post treatment 12 weeks in open phasePolyp size\
Nasal symptoms including olfactionAt week 12 polyp size reduction achieved in FPND groups (24% and 41%)\
Significant improvement in olfactory functionHigher dose of FPND may have resulted in significant effect on olfactory recoveryLund et al. \[[@CR58]\]Severe polyposis.\
FPANS (*n* = 10), beclomethasone dipropionate aqueous nasal spray (*n* = 10), placebo (*n* = 9)\
12 weeks of treatment, 2 weeks of follow-upNeed for polypectomy\
Nasal symptoms including anosmiaNo significant difference in polyp size; no effect on sense of smellStudy enrolled subjects with very severe polyposis\
While there was no effect on anosmia, rhinitis decreased significantlyKeith et al. \[[@CR59]\]Nasal polyps\
FPND (*n* = 52), placebo (*n* = 52), 12 weeks of treatment. 12 weeks open extension (all received FPANS)Need for polypectomy\
Nasal symptoms including anosmiaPolyp size reduction 27% vs. 16%\
Nasal blockage cleared 55% vs. 22%\
No significant difference of effects on olfactory functionFPNS has low systemic bioavailability (0.6% vs. that of FPANS (0.51%)*FESS* functional endoscopic sinus surgery, *INFP* intranasal fluticasone propionate, *FPND* fluticasone propionate nasal drops, *FPANS* fluticasone propionate aqueous nasal spray, *PNIF* peak nasal inspiratory flow rate, *TDI score* threshold, determination, and identification score

Plausibility {#Sec11}
------------

Plausibility is when credible and logical explanations are available to support an observed association. Biological and mechanistic plausibility is an important element of causal inference. In the context of pharmacovigilance, plausibility focuses on the mechanism of action and effects of the medicine in relation to the adverse event.

Like other corticosteroids, FP has potent anti-inflammatory effects. It acts at the intracellular glucocorticoid receptor level via modification of transcription; the resulting range of cellular consequences are described as downregulation of pro-inflammatory molecules and cells (Langerhans cells, lymphocytes, mast cells, eosinophils, and basophils) and upregulation of anti-inflammatory molecules. In the context of intranasal corticosteroids, it is not known whether nasal mucosal penetration per se is sufficient or the penetration beneath the mucous membrane and access to systemic circulation is necessary for the medicine to exert its clinical effects. However, because of the very low systemic exposure of INFP at clinically achieved doses, clinical benefit is thought to be primarily due to nasal mucosal actions \[[@CR45]\].

Eosinophil-mediated inflammation is characteristic of allergic rhinitis and nasal polyposis \[[@CR45], [@CR46]\]. Correlation between sinus mucosal eosinophil counts and clinical olfactory impairment has been shown in allergic rhinitis and nasal polyposis \[[@CR47], [@CR48]\]. INFP therapy in allergic rhinitis reduces eosinophils on the mucosal surface, epithelium, lamina propria, and blood after allergen challenge. Also, INFP therapy appears to reduce the degranulation propensity of eosinophils in the nose and in the circulation \[[@CR49], [@CR50]\]. Importantly, concentration-dependent induction of apoptosis of human eosinophils on exposure to clinically achieved concentrations of FP has been demonstrated \[[@CR51]\]. Similar studies on taste disturbances are not available. Alterations or loss of sense of smell and taste cannot be explained by the established knowledge of the mechanism of action and clinical effects of corticosteroids. Evidence of biologic or mechanistic plausibility that smell and taste disturbances are attributable to INFP is lacking.

INFP has been shown to reduce intranasal inflammation, restore patency of nasal passages, and reduce mucosal congestion leading to reduced mucus secretion in subjects with allergic rhinitis. These effects in turn restore airway access to the 6 million olfactory neurons housed in an area approximately 2 cm^2^ at the roof of the nasal cavity (olfactory cleft) leading to re-establishment of entry of odor chemicals that are essential for chemosensory transmission and odor perception. In nasal polyposis, INFP has been shown to produce the classic anti-inflammatory effects detailed above and reduce polyp size, reduces vascularity of the polyps, and restores access to the osteomeatal complex during surgical removal of polyps, with reduced risk of perioperative bleeding. Overall these effects would help improve olfaction. The known mechanism of action and anti-inflammatory effects of corticosteroids provide adequate explanation for the observed beneficial effects of INFP on olfactory dysfunction and collateral improvement in gustation.

It should be noted that complete or adequate recovery of smell and taste dysfunction occurs in more than two-thirds of patients over the long term (2--3 years) after cessation of the causative exposure \[[@CR52], [@CR53]\]. Therefore, spontaneous recovery is likely to confound and lead to the post hoc *ergo propter hoc* fallacy. No studies to date have addressed this question.

Coherence {#Sec12}
---------

Coherence asks whether interpretation of an observed association is compatible with the known natural history, biology, and general understanding of the disease. While plausibility aims to explore and identify mechanistic hypotheses to support causal inference, coherence seeks to ensure if such inference is credible and aligned to the current knowledge.

The question is whether determination of causality between INFP treatment and dysfunction of smell and taste would be aligned with the current understanding of allergic rhinitis, nasal polyps, and smell and taste disorders. Such determination would indeed conflict with what is currently known about allergic rhinitis, nasal polyps, and smell and taste disorders. As described above (see "[Plausibility](#Sec11){ref-type="sec"}"), the current understanding of allergic rhinitis, nasal polyposis as well as the mechanism of action and clinical benefits of INFP on smell and taste disturbances together present a coherent body of knowledge.

Hill observed that the coherence would change over time because of newer findings and advances. Accordingly, recent findings in this context were reviewed. INFP contains phenyl ethyl alcohol (PEA), an excipient that serves as an antimicrobial preservative and imparts a pleasant floral scent. During regular use of INFP, the repeated exposure to PEA may contribute to olfactory impairment due to *olfactory adaptation* (reduced perception of smell upon repeated or continuous exposure), which is a well-known phenomenon; volunteer studies have shown that olfactory adaptation occurs during PEA exposure \[[@CR54]\]. However, adaptation studies in patients with allergic rhinitis or nasal polyposis are not available. Intriguingly, PEA is also used as an additive in cigarettes, and smoking is a known risk factor for significant olfactory dysfunction \[[@CR55]\]. A recent study of odor perception in smokers demonstrated significant and extended impairment of odor perception and the degree of impairment correlated with duration of smoking; the findings remained significant after adjusting for confounding due to PEA in the cigarettes \[[@CR56]\]. It is hypothesized that smoking induces olfactory neuronal apoptosis leading to disruption of olfactory epithelium \[[@CR56]\]. One large study (*n* = 1144 subjects) showed that at least 20% of patients with allergic rhinitis were active smokers \[[@CR57]\].

The clinical significance of PEA exposure and olfactory adaptation (desensitization and recovery) in the context of allergic rhinitis, nasal polyposis, and corticosteroid exposure is unknown. The effects of repeated exposure to PEA via medication or smoking may contribute to olfactory and gustatory dysfunction but are not fully understood; further studies are required.

None of the putative mechanisms of drug-induced dysfunction of smell and taste (see "[Introduction](#Sec1){ref-type="sec"}") have been shown to be relevant to the known pharmacological actions and effects of INFP. Furthermore, literature search did not find insights or proposed mechanisms specific to smell and taste disturbances associated with INFP.

Experiment {#Sec13}
----------

Hill noted that well-designed experiments may provide strong evidence to support causality. Given the nascent birth of clinical trials circa 1965 when he introduced the criteria, *experiment* as originally defined did not specifically refer to clinical trials. In the context of pharmacovigilance, experiments have been interpreted to include anecdotal reports, clinical trials, and animal experiments, although the clinical significance of the last of these is largely unknown as extrapolation to humans is challenging.

### Clinical Trials {#Sec14}

A search of literature and clinical trial databases did not find studies that reported smell and taste dysfunction due to treatment with INFP.

On the contrary, INFP has been shown to improve olfaction in allergic rhinitis and nasal polyps in randomized controlled clinical trials, and one trial reported improved sense of taste as well \[[@CR42]\]. The trials used different study designs, methods, and sample sizes. Three trials did not find significant effects on olfaction \[[@CR58]--[@CR60]\]; 11 studies \[[@CR42]--[@CR44], [@CR61]--[@CR68]\] that totaled 866 patients treated with INFP from 3 months to 5 years showed significant improvements in olfaction (see Table [1](#Tab1){ref-type="table"} for summary of the studies).

A prospective observational study in patients with mild, moderate, or severe perennial allergic rhinitis (PAR) treated with intranasal azelastine 548 mcg + INFP 200 mcg once daily reported significant beneficial effects on anosmia and nasal symptoms; 93--96% patients achieved complete recovery of normal sense of smell at 1 month of therapy with further complete recovery of olfaction achieved in 100% of patients at 3 months of therapy \[[@CR68]\]. This was the first and only study to report full recovery of olfaction in all participants. It may be noted that azelastine is reported to have an especially bitter taste and the combination product is labeled for "disturbances or loss of smell and taste". Unfortunately, effects on taste were not assessed in this trial; however, the findings suggest that INFP may contribute to complete restoration of the sense of smell. Given the limitations of this study, further trials are required. Other clinical trials show that INFP significantly improves olfactory dysfunction. However, there is a paucity of clinical trials that address the effects of INFP on taste dysfunction.

### Other Experiments {#Sec15}

In 22 patients with nasal polyposis the effects of FPANS 200 mcg per day for 2 weeks on the induction of apoptosis of infiltrating inflammatory cells in explants from post-treatment biopsies was assessed. Explants of polyps were also exposed to dexamethasone to assess effects on apoptosis. While FPANS showed little effect on apoptosis, dexamethasone induced significant apoptosis \[[@CR69]\]. The clinical significance of these findings is not known. In contrast, Zhang et al. compared induction of apoptosis of human eosinophils after exposure to FP, budesonide, beclomethasone, and dexamethasone. Fluticasone propionate produced twofold increase in eosinophil apoptosis compared to controls at clinically achievable drug concentrations, was equipotent to budesonide but significantly more potent than beclomethasone and dexamethasone \[[@CR51]\]. As discussed previously reduced eosinophil count correlates with improvement in olfactory performance.

A literature search found no clinical or experimental evidence to suggest causal link between smell and taste dysfunction and exposure to INFP.

Analogy {#Sec16}
-------

In the context of pharmacovigilance, analogy is interpreted as similar evidence from another drug in the same class. Corticosteroids are one of the largest class of medicines. Oral and injectable administration of different doses has shown clinically beneficial and occasionally dramatic improvements in patients with long-standing smell loss. Clinical trials of other intranasal corticosteroids (budesonide and mometasone) have shown clinical benefits on olfactory disturbances in patients with nasal polyposis \[[@CR70]--[@CR79]\]. In a pilot study of patients with seasonal allergic rhinitis (SAR), treatment with intranasal mometasone furoate for 2 weeks was associated with significant reduction in inflammation of olfactory cleft mucosa, reduction of eosinophils in olfactory epithelium, and improvement in olfactory quality of life \[[@CR80]\]. This study showed that inflammation in SAR can affect the olfactory cleft and suggests direct role for allergic inflammation in smell loss.

Empirical oral or parenteral administration of large doses of corticosteroids is reported to result in recovery of olfaction. A single dose of 17.1 mg betamethasone administered via epidural injection for acute back pain in a 42-year-old man with previous history of complete loss of smell 15 years prior was reported to result in dramatic complete recovery of sense of smell within 24 h of the injection. This report was aptly titled "The sweet smell of success" \[[@CR81]\]. Anecdotal use of oral prednisolone 40 mg per day for 4 weeks resulted in adequate recovery of taste in a patient with trigeminal neuropathy due to systemic sclerosis \[[@CR82]\]. Orally or parenterally administered prednisolone is known to improve olfaction in some patients with anosmia due to traumatic and sinonasal disease \[[@CR83]--[@CR86]\].

Limitations {#Sec17}
===========

This causality assessment has a number of limitations. First, patients are unable to distinguish between smell and taste disturbances in general. Second, in patients with allergic rhinitis and nasal polyps there is high background prevalence of smell and taste disturbances. Third, concurrent medications (e.g., antibiotics, intranasal zinc) used in the treatment of upper respiratory tract infections, which commonly complicate allergic rhinitis and nasal polyps, are known to be associated with smell and taste disturbances. As a result of these factors smell and taste alterations are inextricable and were considered as a single entity for the purpose of this causality assessment. Fourth, as a result of anatomical, physiological, and perceptual overlaps in perception of smell and taste, the potential improvement in olfaction due to INFP may result in secondary improvement in taste but there is lack of studies that have addressed this question. Fifth, the total number of ICSRs with smell and taste alterations was 914, which represents significant underreporting. Sixth, the quality of the narratives of the majority of ICSRs was inadequate to support meaningful analysis, interpretation, and extrapolation. Finally, literature, known pharmacology, and nosology provide adequate information to assess eight Hill's criteria, namely *strength of association*, *consistency*, *specificity*, *temporality*, *plausibility*, *coherence*, *experiment*, and *analogy*; however, the evidence to assess *biological gradient* is rather limited.

Conclusion {#Sec18}
==========

Randomized controlled clinical trials comparing patients with allergic rhinitis treated with INCS or topical antihistamines to healthy subjects treated with INCS may provide conclusive evidence.

In this review the *strength of the association* between exposure to INFP and olfactory and gustatory dysfunction was found to be weak because of the preponderance of these events in the general population and patients with allergic rhinitis and nasal polyps compared with those exposed to INFP. No patterns of *consistency* and *specificity* of the drug--event pairs were observed. Presence of smell and taste dysfunction *prior to therapy* with INFP in cases of allergic rhinitis and nasal polyposis cannot be ruled out and therefore *temporality* cannot be established. There is no evidence to support a positive dose--response relationship (*biologic gradient*) between exposure to INFP and the degree of olfactory and gustatory impairment. On the basis of the known biology and natural history of allergic rhinitis and nasal polyposis and the mechanism of action and effects of INFP, there is lack of *plausibility*. As the notion of causal link between exposure to INFP and olfactory and gustatory dysfunction would fundamentally conflict with the current understanding of allergic rhinitis and nasal polyposis, *coherence* is conspicuous by absence. Randomized controlled trials (*experiment*) show consistent clinical benefits of INFP and other intranasal corticosteroids in patients with smell and taste disorders. Corticosteroids administered via oral or injectable routes are known to provide beneficial effects on smell and taste disorders (*analogy*). In summary, application of Hill's criteria finds that INFP treatment is not causally linked to smell and taste disturbances.

Perhaps Sir Bradford Hill would agree that on the basis of evidence for this observed association the *verdict of causation shall not pass.*
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